Healthcare Jan 05, 2022 11:24 AM (GMT+8)
On January 1, the national medical insurance drug catalogue was officially launched. As the first Chinese original class I new drug approved for the treatment of platinum sensitive and platinum resistant recurrent ovarian cancer, baihuize, a PARP inhibitor independently developed by Baiji Shenzhou ® (pamipali capsule) has been included in the medical insurance catalogue for the treatment of patients with recurrent advanced ovarian cancer, fallopian tube cancer or primary peritoneal cancer with germline BRCA (gbrca) mutation after second-line or above chemotherapy.
It is reported that baihuize ® After entering the medical insurance, the price decreased from 7000 yuan per box (60 Tablets, specification 20mg) to 3216 yuan, a decrease of 54%.
Ovarian cancer is one of the malignant tumors that seriously threaten women's health. In China, the incidence rate of ovarian cancer is third in the female reproductive system and the trend is increasing year by year.
At present, the clinical treatment methods are mainly surgery and postoperative platinum chemotherapy. Ovarian cancer is very easy to relapse. After the initial treatment of surgery and chemotherapy, the 3-year recurrence rate of patients is about 70%. After multiple relapses, the sensitivity of patients to platinum drugs will become worse and worse, and finally develop into platinum resistant relapse. Patients with relapse of platinum resistance usually choose non platinum drugs for chemotherapy. The treatment scheme is limited and the effect is often not ideal.
Baihuize ® Focusing on the treatment of platinum sensitive and platinum resistant recurrent ovarian cancer, as the only known PARP inhibitor of non drug pump (P-gp) substrate, low drug resistance brings potentially longer progression free survival and delay recurrence.
This text is a result of machine translation.